Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2157)	11/30/2000 8:00:12 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4974

Tuck, Your example is sort of defense toward hostile takeover. I am talking about merge where synergy in business model (people, programs, cash,…) is warranted. Combined comp may/will do better than single entity. Shareholders may benefit regardless what is merge/premium price (if one is looking long term and not short quick profit). <<Given the ongoing "revaluation" of biotechs, >. This is going both ways, valid for bios but as well as for its competitors. So, it is not point of undervalued or overvalued, will they be able to survive future? Miljenko